Allergy Therapeutics (LSE:AGY) FCF Margin %: -40.21% (As of Dec. 2025)


What is Allergy Therapeutics FCF Margin %?

Allergy Therapeutics LSE:AGY FCF Margin % is -40.21% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 958 Drug Manufacturers companies, Allergy Therapeutics ranks worse than 90.61% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Allergy Therapeutics's Free Cash Flow for the six months ended in Dec. 2025 was £-14.59 Mil. Allergy Therapeutics's Revenue for the six months ended in Dec. 2025 was £36.28 Mil. Therefore, Allergy Therapeutics's FCF Margin % for the quarter that ended in Dec. 2025 was -40.21%.

As of today, Allergy Therapeutics's current FCF Yield % is -8.40%.

The historical rank and industry rank for Allergy Therapeutics's FCF Margin % or its related term are showing as below:

LSE:AGY' s FCF Margin % Range Over the Past 10 Years
Min: -65.02   Med: -16.1   Max: 12.71
Current: -65.02

During the past 13 years, the highest FCF Margin % of Allergy Therapeutics was 12.71%. The lowest was -65.02%. And the median was -16.10%.

LSE:AGY's FCF Margin % is ranked worse than
90.61% of 958 companies
in the Drug Manufacturers industry
Industry Median: 2.445 vs LSE:AGY: -65.02

Allergy Therapeutics FCF Margin % Related Terms

Allergy Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Allergy Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allergy Therapeutics FCF Margin % Chart

Allergy Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.15 -23.44 -56.30 -64.38 -57.28

Allergy Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.65 -105.89 -26.05 -107.86 -40.21

LSE:AGY vs ZTS, UTHR, VTRS: FCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allergy Therapeutics FCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's FCF Margin % falls into.


Allergy Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Allergy Therapeutics's FCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-31.531/55.044
=-57.28 %

Allergy Therapeutics's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-14.588/36.28
=-40.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -40.21% mean?
Allergy Therapeutics (LSE:AGY) has a FCF Margin % of -40.21% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Allergy Therapeutics and its competitors. According to the industry distribution chart, Allergy Therapeutics ranks #868 out of 958 companies in the Drug Manufacturers industry, placing it in the top 90.6%.
Is Allergy Therapeutics' FCF Margin % too high?
Allergy Therapeutics' current FCF Margin % is -40.21%. Based on the distribution chart, Allergy Therapeutics ranks #868 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Allergy Therapeutics' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allergy Therapeutics ranks #868 out of 958 companies for FCF Margin %. This places Allergy Therapeutics in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Allergy Therapeutics and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allergy Therapeutics's current FCF Margin % is -40.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (LSE:AGY) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.03, compared to a current price of £0.07 — trading 133.3% above its estimated fair value. The current FCF Margin % is -40.21%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Allergy Therapeutics (LSE:AGY), the current FCF Margin % is -40.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allergy Therapeutics Business Description

Other Exchanges AGYTF:USAHHU:Germany
Address Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).